These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Induction of uterine contractions using Enzaprost F administered into the uterine cavity].
    Author: Marianowski L, Nowakowska-Kosmalska B.
    Journal: Ginekol Pol; 1986 Sep; 57(9):570-2. PubMed ID: 3468046.
    Abstract:
    In a clinical trial carried out in 34 pregnancy women Enzaprost F 4 (prostaglandin F2-alpha) was administered into the uterus to cause uterine contractions in the 2nd and 3rd trimesters. The indications for the treatment were: 1. membrane rupture in 20 cases between the 21st and 26th weeks of pregnancy; 2. fetal death in 12 cases between the 24th and 34th weeks of pregnancy, and 3. induced abortion for medical reasons in 2 cases of primiparae in the 2nd trimester. Enzaprost was administered in physiological salt solution in doses of 2-5 mg with a total dose of 9-22 mg (average 18.5 mg). Contractions appeared within 15-30 minutes in groups 1 and within 20-30 minutes in groups 2 and 3. Abortions in the three different groups began 10.2, 11.5, and 6.0 hours after administration in primiparae and 7.3 and 8.2 hours, respectively, after treatment in groups 1 and 2 in women other than primiparae. Oxytocin had to be administered additionally in 3 cases in groups 1 and 2. The method proved to be safe and effective, side effects occurred in 6 cases (17.6%) consisting of cardiac pain, nausea, tachycardia, and increased systolic pressure.
    [Abstract] [Full Text] [Related] [New Search]